Business Context and Reporting Period
Company: Omeros Corporation (OMER)
Filing Type: Form 8-K (Current Report)
Date of Report: October 10, 2025
Event: Entry into a Material Definitive Agreement (Asset Purchase and License Agreement) with Novo Nordisk Health Care AG.
Key Financial Metrics and Transaction Terms
This filing details a strategic transaction rather than periodic financial performance. Key financial terms include:
- Total Potential Consideration: Up to $2.1 billion in upfront and milestone-based payments.
- Upfront Payment: $240.0 million cash payable at closing.
- Development Milestones: Up to $510 million upon achievement of specific development and approval events.
- Sales Milestones: Up to $1.3 billion upon achievement of sales-based events.
- Royalties: Tiered royalties on annual net sales ranging from high single-digit to high-teens percentages.
- Debt Repayment: A portion of the upfront payment will be used to repay $67.1 million in outstanding term loans under the Company's Credit Agreement, along with related premiums and interest.
Material Changes and Asset Transfer
Asset Transfer: Omeros is transferring exclusive global rights to develop and commercialize zaltenibart (OMS906), its lead human monoclonal antibody targeting MASP-3, along with related compounds and products to Novo Nordisk.
Retained Rights: Omeros retains rights to its existing MASP-3 small-molecule program and "grandfathered" MASP-3 antibodies (subject to temporal and indication restrictions).
Restrictions: The Company is restricted from exploiting products directed to MASP-3 and certain alternative pathway targets, with exceptions for retained preclinical programs and non-competing indications.
Outlook, Risks, and Management Commentary
Closing Timeline: The transaction is expected to close in the fourth quarter of 2025, subject to customary conditions including regulatory approvals (Hart-Scott-Rodino), absence of material adverse effects, and satisfaction of representations and warranties.
Transition Services: Omeros will provide transition services to Novo Nordisk post-closing to facilitate asset transfer and continued study operations, with costs reimbursed by Novo Nordisk.
Risks and Contingencies:
- The transaction is subject to termination if closing does not occur by a specified date or if a governmental order prohibits the deal.
- Forward-looking statements regarding payment expectations are subject to risks associated with product commercialization, regulatory processes, and other factors detailed in the Company's 2025 Form 10-K.
Investor Verification Checklist
- Verify the final closing date and confirmation of the $240.0 million upfront payment receipt.
- Confirm the full repayment of the $67.1 million term loan and the release of associated liens.
- Monitor regulatory approval status under the Hart-Scott-Rodino Act.
- Review the specific definitions of "development and approval milestone events" and "sales-based milestone events" in the definitive agreement to assess probability of future payments.
- Assess the impact of retained rights on the Company's future small-molecule pipeline.